Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Allogene Therapeutics, Inc. (ALLO) incurred an adjusted loss (excluding impairment of long-lived asset) of 32 cents per share in second-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 35 cents.Inclusive of impairment charges, the company posted a loss of 35 cents in the second quarter. In the year-ago period, the company reported a loss of 54 cents. There was no impairment charge recorded in the year-ago period.ALLO did not generate any revenues during the quarter. The Zacks Consensus ...